Don't want ads? Subscribe or login now.

Drugmaker Fights Claims Over 'Misleading' IPO Statements

By Emilie Ruscoe · July 11, 2025, 12:29 PM EDT

Investors in biopharmaceutical company BioAge Labs Inc. mischaracterized certain statements the company made in an effort to allege securities fraud after the company hit the brakes on a clinical trial for...

To view the full article, register now.

Try a seven day FREE Trial

Already a subscriber? Click here to login

Documents

Memorandum

Case Information

Case Title

Soto v. BioAge Labs, Inc. et al

Case Number

3:25-cv-00196

Court

California Northern

Nature of Suit

Securities/Commodities

Date Filed

January 07, 2025

Recent Articles By Emilie

July 10, 2025
Brookdale's $1.9M Deal Ends Investor Suit On Understaffing
June 23, 2025
Teladoc Says Investor Suit Over User Losses Is 'Illogical'
May 15, 2025
Ex-CEO Cops To Conspiracy Charge In $212M Fraud Case
May 14, 2025
Actinium Faces Derivative Suit Over FDA Application Claims
May 13, 2025
Health Co. Elevance Faces Suit Over Post-COVID Costs Claims
April 29, 2025
Acadia Investors Seek Partial Win, Sanction In Healthcare Suit
March 24, 2025
Investors Blame Electrotherapy Co.'s Practices For Stock Drop
January 07, 2025
Obesity Drug Maker Faces Investor Suit Over IPO Disclosures
January 06, 2025
Biotech Co. Revance Faces Suit After Tender Offer Weakens
January 02, 2025
Eye Drug Study Blindsided Pharma Co. Investors, Suit Says